← ANALYST RATINGS · TIPRANKS
Inhibrx Biosciences Inc (INBX): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy0 Hold0 Sell
Ratings of 2 analysts in the last 3 months · top analysts only12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $238, the highest $245, the lowest $230. The average is +164.4% from the last price of $89.83.
Analyst ratings 3
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $87.00 → $92.00+5.7% | Hold | +2.4% | Reiterated | 17.10.26on TipRanks 06:07 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $86.00 → $91.00+5.8% | Hold | +1.3% | Reiterated | 17.10.26on TipRanks 05:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $84.00 → $88.00+4.8% | Hold | −2.0% | Reiterated | 17.10.26on TipRanks 05:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $80.00 → $84.00+5.0% | Sell | −6.5% | Downgrade | 17.10.26on TipRanks 05:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $91.00 → $96.00+5.5% | Hold | +6.9% | Reiterated | 17.10.26on TipRanks 05:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $86.00 → $90.00+4.7% | Hold | +0.2% | Reiterated | 17.10.26on TipRanks 05:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $89.00 → $87.00−2.2% | Hold | −3.2% | Reiterated | 16.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $88.00 → $86.00−2.3% | Hold | −4.3% | Reiterated | 16.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $85.00 → $84.00−1.2% | Hold | −6.5% | Reiterated | 16.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $81.00 → $80.00−1.2% | Sell | −10.9% | Downgrade | 16.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $93.00 → $91.00−2.2% | Hold | +1.3% | Reiterated | 16.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $88.00 → $86.00−2.3% | Hold | −4.3% | Reiterated | 16.10.26on TipRanks 00:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $92.00 → $89.00−3.3% | Hold | −0.9% | Reiterated | 14.10.26on TipRanks 18:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $91.00 → $88.00−3.3% | Hold | −2.0% | Reiterated | 14.10.26on TipRanks 18:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $89.00 → $85.00−4.5% | Hold | −5.4% | Reiterated | 14.10.26on TipRanks 18:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $85.00 → $81.00−4.7% | Sell | −9.8% | Downgrade | 14.10.26on TipRanks 18:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $96.00 → $93.00−3.1% | Hold | +3.5% | Reiterated | 14.10.26on TipRanks 18:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $91.00 → $88.00−3.3% | Hold | −2.0% | Reiterated | 14.10.26on TipRanks 18:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $95.00 → $92.00−3.2% | Hold | +2.4% | Reiterated | 13.10.26on TipRanks 13:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $94.00 → $91.00−3.2% | Hold | +1.3% | Reiterated | 13.10.26on TipRanks 13:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $91.00 → $89.00−2.2% | Hold | −0.9% | Reiterated | 13.10.26on TipRanks 13:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $87.00 → $85.00−2.3% | Sell | −5.4% | Downgrade | 13.10.26on TipRanks 13:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $99.00 → $96.00−3.0% | Hold | +6.9% | Reiterated | 13.10.26on TipRanks 13:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $93.00 → $91.00−2.2% | Hold | +1.3% | Reiterated | 13.10.26on TipRanks 13:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $94.00 → $93.00−1.1% | Hold | +3.5% | Reiterated | 09.10.26on TipRanks 11:07 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $92.00 → $91.00−1.1% | Hold | +1.3% | Reiterated | 08.10.26on TipRanks 05:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $104 → $95.00−8.7% | Hold | +5.8% | Reiterated | 07.10.26on TipRanks 03:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $103 → $94.00−8.7% | Hold | +4.6% | Reiterated | 07.10.26on TipRanks 03:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $100 → $92.00−8.0% | Hold | +2.4% | Reiterated | 07.10.26on TipRanks 03:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $95.00 → $87.00−8.4% | Sell | −3.2% | Downgrade | 07.10.26on TipRanks 03:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $108 → $99.00−8.3% | Hold | +10.2% | Reiterated | 07.10.26on TipRanks 03:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $102 → $94.00−7.8% | Hold | +4.6% | Reiterated | 07.10.26on TipRanks 03:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $106 → $104−1.9% | Hold | +15.8% | Reiterated | 29.09.26on TipRanks 01:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $106 → $103−2.8% | Hold | +14.7% | Reiterated | 29.09.26on TipRanks 01:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $104 → $100−3.8% | Hold | +11.3% | Reiterated | 29.09.26on TipRanks 01:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $105 → $95.00−9.5% | Sell | +5.8% | Downgrade | 29.09.26on TipRanks 01:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $109 → $108−0.9% | Hold | +20.2% | Reiterated | 29.09.26on TipRanks 01:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $104 → $102−1.9% | Hold | +13.5% | Reiterated | 29.09.26on TipRanks 01:05 | — | |
| Robert Burns★★★★★★★★★★#272 · hits 52% · avg +25.9% | H.C. Wainwright | $245 | Buy | +172.7% | Reiterated | 09.09.26on TipRanks 07:25 | −0.8%next day −0.7% · 5 days −8.7% | ↗ |
| Oliver McCammon★★★★★★★★★★#315 · hits 48% · avg +70.9% | LifeSci Capital | $230 | Buy | +156.0% | Reiterated | 08.09.26on TipRanks 09:35 | −5.1%next day −0.8% · 5 days −6.5% | ↗ |
| Dara Azar★★★★★★★★★★#9877 · hits 33% · avg −5.2% | Stifel Nicolaus | $325 | Buy | +261.8% | Reiterated | 21.08.26on TipRanks 06:50 | +4.1%next day +1.6% · 5 days +18.6% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Inhibrx Biosciences Inc
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $267 at a price of $100 (+166.5%); now: $267 at $89.83 (+196.9%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 2 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 13.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-2.45 (from $-2.63 to $-2.14). Last quarter: $-2.34.
Sales
Next quarter’s sales estimate — $0M (from $0M to $0M). Last quarter: $0M.
Best top-analyst consensus in the sector · General
About Inhibrx Biosciences Inc
- CEO: Mark Lappe
- Employees: 110
- 11025 North Torrey Pines Road, La Jolla, CA, 92037, US
- www.inhibrx.com
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
Data from the stock’s TipRanks forecast page, read 209 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗